Roflumilast cream (ZORYVE; Arcutis) has shown efficacy in treating atopic dermatitis (AD) and reducing its impact on patients and families, according to new patient-reported outcome (PRO) data from the INTEGUMENT-1 and -2 studies. These findings were presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting. The results highlight the potential of roflumilast to improve the quality of life for individuals and families affected by this chronic skin condition.
Impact on Patient-Reported Outcomes
The PRO data indicated that 64.2% of participants in the roflumilast group experienced a clinically meaningful improvement in SCORAD Total Score compared to 36.3% in the vehicle group at Week 1 (P < .0001). At Week 4, 46.2% of the roflumilast group showed clinically meaningful improvement compared to 26.6% in the vehicle group (P < .0001). Furthermore, 61.7% of the roflumilast group had a clinically meaningful improvement in POEM scores compared to 34.2% in the vehicle group at Week 1 (P < .0001), with greater improvement seen in the roflumilast group at Week 4 (7.5 vs. 3.9; P < .0001). Improvement was also observed in DFI scores in the roflumilast group compared to the vehicle group at Week 4 (3.12 vs. 1.74; P < .0001).
Expert Commentary
Mark Boguniewicz, MD, Professor, Pediatric Allergy /Immunology /Rheumatology, University of Colorado, and National Jewish Health, and Children's Hospital Colorado, stated, "AD is a chronic, complex disease that can negatively affect the individual and the broader family unit, impacting relationships, sleep, and basic functions in life, like school attendance, housework, food preparation, and more. These new data show that treatment with ZORYVE not only provides rapid disease clearance and significant reduction in itch for the patient, but extends beyond that, reducing the impact of quality of life challenges that families and caregivers experience as a result of having a loved one living with a chronic skin disease like AD."
About the INTEGUMENT Studies
The INTEGUMENT-1 and INTEGUMENT-2 Phase 3 trials were identical parallel-group, double-blind, vehicle-controlled trials. They evaluated the safety and efficacy of ZORYVE cream 0.15% or vehicle applied once daily for 4 weeks in 1,337 adults and children aged 6 years and older with mild to moderate AD.
Roflumilast: Mechanism and Approval
Roflumilast cream is a next-generation topical phosphodiesterase-4 (PDE4) inhibitor designed to decrease the production of pro-inflammatory mediators and increase the production of anti-inflammatory mediators. It was approved for treating individuals aged 6 years and older with moderate-to-severe AD in July 2024, following an initial approval for plaque psoriasis in 2022.
Arcutis' Perspective
Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis, added, "When evaluating different treatment options for chronic skin conditions we often focus on the clinical efficacy outcomes, like disease clearance or reduction in symptoms like itch. However, this is just one piece of the puzzle and it’s just as important to understand the improvement in other aspects of patients’ lives that are impacted by this chronic disease. We’re proud to share these data showcasing rapid improvement in patient reported outcomes, which translate to meaningful relief with ZORYVE cream for those with AD their families, and caregivers."
